SUVEN360.00

Suven Life Sciences Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersVIMTALABSTAKEMcap ₹9,494 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations11.76.77.18.8
Other Income21.110.913.920.9
Total Income32.817.621.029.7
Expenses
+ Employee Benefit Expense19.020.824.125.5
+ Finance Costs0.20.00.20.6
+ Depreciation & Amortisation6.55.85.66.4
+ Other Expenses120.7151.6267.5349.6
Total Expenses146.4178.3297.4382.1
EBITDA-128.0-165.8-284.5-366.3
EBIT-134.5-171.6-290.1-372.7
Profit
PBT before Exceptional Items-113.5-160.7-276.3-352.4
+ Exceptional Items7.50.00.00.0
Pretax Income-106.1-160.7-276.3-352.4
+ Current Tax-1.00.00.00.0
Tax Expense-1.00.00.00.0
Net Income-105.1-160.7-276.3-352.4
+ Net Income — Continuing Ops-105.1-160.7-276.3-352.4
+ Other Comprehensive Income-0.1-0.6-1.2-1.2
Total Comprehensive Income-105.1-161.3-277.5-353.6
Per Share
Basic EPS-4.82-7.37-12.13-14.89
Diluted EPS-4.82-7.37-12.13-14.89
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.6-1.2-1.2
+ Items NOT to be Reclassified to P&L-0.6-0.2-0.2
+ Tax on Items NOT to be Reclassified — alt tag0.1
+ Items to be Reclassified to P&L-1.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-4.82-7.37-12.13-14.89
Diluted EPS — Continuing Operations-4.82-7.37-12.13-14.89
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit11.76.77.18.8
Gross Margin %100.00100.00100.00100.00
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-113.5-160.7-276.3-352.4
− Exceptional Items (reconciliation)7.50.00.00.0
Net Income Adj (tax-effected)-112.5-160.7-276.3-352.4
EPS Adj-5.16-7.37-12.13-14.89
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital21.821.826.426.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.